San Francisco, CANCT06959524Now EnrollingIRB Ready

Coronary Arterial Disease (CAD) Clinical Trial in San Francisco, CA

Access cutting-edge coronary arterial disease (cad) treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Boston Scientific Corporation

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access coronary arterial disease (cad) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related coronary arterial disease (cad) treatment provided free

Apply for This San Francisco Location

Check if you qualify for this coronary arterial disease (cad) clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Coronary Arterial Disease (CAD) Study in San Francisco

AGENT DCB STANCE is a prospective, multicenter, open-label, 1:1 randomized controlled study designed to assess the safety and effectiveness of a treatment strategy with the AGENT Drug-Coated Balloon compared to standard of care percutaneous coronary intervention (PCI) treatment with drug eluting stent (DES) and/or balloon angioplasty in patients with de novo coronary lesions. Subjects must have a de novo target lesion located in a native coronary artery.

Sponsor: Boston Scientific Corporation

Who Can Participate

Inclusion Criteria

Subject must be at least 18 years of age.
Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed.
Subject is eligible for percutaneous coronary intervention (PCI).
Subject is willing to comply with all protocol-required follow-up evaluation.
Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure. Angiographic Inclusion Criteria:
Target lesion is a de novo lesion located in a native coronary artery
Target lesion must have visually estimated stenosis \> 50% and \< 100% in symptomatic subjects (\>70% and \<100% in asymptomatic subjects) prior to lesion pre-dilation.
Target lesion must be successfully pre-dilated.
If a non-target lesion is treated, it must be treated first and must be deemed a success. Clinical

Exclusion Criteria

Subject has other serious medical illness (e.g. cancer, congestive heart failure) that may reduce life expectancy to less than 12 months.
Subject has current problems with substance abuse (e.g. alcohol, cocaine, heroin, etc.).
Subject has planned procedure that may cause non-compliance with the protocol or confound data interpretation.
Subject is participating in another investigational drug or device clinical study that has not reached its primary endpoint.
Subject intends to participate in another investigational drug or device clinical study within 12 months after the index procedure.
Subject is a woman who is pregnant or nursing. A pregnancy test must be performed within 7 days prior to the index procedure, except for women who definitely do not have child-bearing potential.
Subject has left ventricular ejection fraction known to be \< 30%.
Subject had PCI or other coronary interventions within the last 30 days.
Subject has planned PCI or CABG after the index procedure.
Subject had STEMI or QWMI \<72h prior to the index procedure.
Subject presents with NSTEMI and rising biomarkers, or ongoing chest pain or is hemodynamically unstable.
Subject has cardiogenic shock (SBP \< 80 mmHg requiring inotropes, IABP or fluid support).
Subject has history (within 6 months prior to the index procedure) of New York Heart Association (NYHA) class III or IV heart failure.
Subject is considered not able to tolerate at least 30 seconds of coronary occlusion of the target lesion.
Subject has known allergy to paclitaxel or other components of the used medical devices.
Subject has known hypersensitivity or contraindication to contrast dye that in the opinion of the investigator cannot be adequately pre-medicated.
Subject has intolerance to antiplatelet drugs, anticoagulants required for procedure.
Subject has platelet count \< 100k/mm3 (risk of bleeding) or \> 700k/mm3.
Subject with renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent). Angiographic Exclusion Criteria:
In-stent restenosis.
Target lesion is located within a saphenous vein or arterial graft.
Target lesion is a total occlusion or has evidence of thrombus present in the target vessel.
Target lesion is severely calcified by angiography or has \> 270° calcium arc on intravascular imaging or requires atherectomy.
Subject has unprotected left main coronary artery disease (\>50% diameter stenosis) or three-vessel coronary disease requiring revascularization of all 3 vessels.
Subject with planned treatment of lesion involving aortic ostial location.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT06959524) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Coronary Arterial Disease (CAD) Treatment Options in San Francisco, CA

If you're searching for coronary arterial disease (cad) treatment options in San Francisco, CA, this clinical trial (NCT06959524) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced coronary arterial disease (cad) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all coronary arterial disease (cad) clinical trials near you to find additional studies recruiting in your area.

More Heart Disease Trials in San Francisco, CA

See all heart disease clinical trials recruiting in San Francisco — not just this study.

Browse Heart Disease Trials in San Francisco →

Browse More Trials by Condition

Heart Disease TrialsAlzheimers Disease TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA